Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: A prospective study

British Journal of Dermatology

Volumn 162, Issue 2, 2010, Pages 427-434

  Wain, E M ^a   Darling, M I ^a   Pleass, R D ^a   Barker, J N W N ^a   Smith, C H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dermatology life quality index (DLQI); Fumaderm; Fumaric acid esters; Psoriasis; Psoriasis area and severity index (PASI)

Indexed keywords

ANTIPSORIASIS AGENT; CYCLOSPORIN A; ETRETIN; FUMADERM; HYDROXYUREA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD EXAMINATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; FLUSHING; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; DERMATOLOGIC AGENTS; FEMALE; FUMARATES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74349131119     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09267.x     Document Type: Article

References (27)

1. Schweckendiek W. Heilung von psoriasis [Treatment of psoriasis vulgaris]. Med Monatsschr 1959 13 : 103 104.
2. Nieboer C, de Hoop D, Langendijk PN et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990 181 : 33 7.
3. Nugteren-Huying WM, van derSchroeff JG, Hermans J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 1990 22 (2 Pt 1 311 312.
4. Sebok B, Bonnekoh B, Geisel J, Mahrle G. Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 1994 270 : 79 87.
5. Litjens NHR, Nibbering PH, Barrois AJ et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with down-regulation of type-1 cytokines. Br J Dermatol 2003 148 : 444 451.
6. De Jong P, Bezemer AC, Zomerdijk TPL et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996 26 : 2067 2074.
7. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001 116 : 203 208.
8. Litjens NHR, Rademaker M, Ravensbergen B et al. Effects of monomethylfumarate on dendritic cell differentiation. Br J Dermatol 2006 154 : 211 217.
9. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003 121 : 1383 1388.
10. Ockenfels HM, Schultewolter T, Ockenfels G et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic network. Br J Dermatol 1998 139 : 390 395.
11. Lehmann JCU, Listopad JJ, Rentzsch CU et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007 127 : 835 845.
12. Rubant SA, Ludwig RJ, Diehl S et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol 2008 128 : 326 331.
13. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effects of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994 30 : 977 981.
14. Griffiths CEM, Clark CM, Chalmers RJG et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000 4 : 1 125.
15. Sladden MJ, Osborne JE, Hutchinson PE. Fumaric acid esters for severe psoriasis: the Leicestershire experience. Br J Dermatol 2006 155 : 843 844.
16. Fika Z, Williams RE, Williamson DJ. Fumaric acid esters in psoriasis. Br J Dermatol 2006 154 : 567 568.
17. Harries MJ, Chalmers RJG, Griffiths CEM. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol 2005 153 : 549 551.
18. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004 150 : 741 746.
19. Mrowietz U, Christophers E, Altmeyer P the Participants in the German Multicentre Study. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br J Dermatol 1998 138 : 456 460.
20. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992 27 (5 Pt 1) : 769 771.
21. Brewer L, Rogers S. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol 2007 32 : 246 249.
22. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003 149 : 363 369.
23. Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005 152 : 597 615.
24. Mrowietz U, Christophers E, Altmeyer PJ. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 1999 141 : 424 429.
25. Finlay AY, Khan GK. Dermatology Life Quality Index. 1992. Available at: http://www.dermatology.org.uk (last accessed 20 October 2008).
26. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998 196 : 223 230.
27. Ahmad K, McDonnell TJ, Rogers S. Does prior treatment with fumaric acid esters predispose to tuberculosis in patients on etanercept? Clin Exp Dermatol 2007 32 : 329.